# LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lba29-final-overall-survival-os-results-from-the-phase-iii-paola-1-engot-ov25/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Isabelle Laure Ray-Coquard,Alexandra Léary,Sandro Pignata,Claire Cropet,Andrew Martin,Gerhard Bogner,Hiroyuki Yoshida,Ignace Vergote,N. Colombo,Jenni Mäenpää,Frédèric Selle,Barbara Schmalfeldt,Giovanni Scambia,Eva María Guerra Alia,Claudia Lefeuvre‐Plesse,A. Belau,Alain Lortholary,Martina Gropp‐Meier,Éric Pujade-Lauraine,P. Harter |
| Citations | 40 |
| DOI | 10.1016/j.annonc.2022.08.025 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.annalsofoncology.org/article/S0923753422039035/pdf |
| OpenAlex ID | https://openalex.org/W4297821473 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Gerhard Bogner](https://scholariq.org/researchers/gerhard-bogner/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Paper topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.